| Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy SA Apostolidis, M Kakara, MM Painter, RR Goel, D Mathew, K Lenzi, ... Nature medicine 27 (11), 1990-2001, 2021 | 438 | 2021 |
| Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy R Li, A Rezk, Y Miyazaki, E Hilgenberg, H Touil, P Shen, CS Moore, ... Science translational medicine 7 (310), 310ra166-310ra166, 2015 | 419 | 2015 |
| MerTK is a functional regulator of myelin phagocytosis by human myeloid cells LM Healy, G Perron, SY Won, MA Michell-Robinson, A Rezk, SK Ludwin, ... The Journal of Immunology 196 (8), 3375-3384, 2016 | 161 | 2016 |
| Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis R Li, A Rezk, M Ghadiri, F Luessi, F Zipp, H Li, PS Giacomini, J Antel, ... The Journal of Immunology 198 (2), 691-698, 2017 | 128 | 2017 |
| Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation I Shaked, RN Hanna, H Shaked, G Chodaczek, HN Nowyhed, G Tweet, ... Nature immunology 16 (12), 1228-1234, 2015 | 127 | 2015 |
| Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis R Li, A Rezk, LM Healy, G Muirhead, A Prat, JL Gommerman, A Bar-Or, ... Frontiers in Immunology 6, 626, 2016 | 117 | 2016 |
| A novel microRNA-132-surtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis Y Miyazaki, R Li, A Rezk, H Misirliyan, C Moore, N Farooqi, M Solis, ... Plos one 9 (8), e105421, 2014 | 95 | 2014 |
| Human mesenchymal stem cells impact Th17 and Th1 responses through a prostaglandin E2 and myeloid-dependent mechanism A Rozenberg, A Rezk, MN Boivin, PJ Darlington, M Nyirenda, R Li, F Jalili, ... Stem cells translational medicine 5 (11), 1506-1514, 2016 | 94 | 2016 |
| Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis M Ghadiri, A Rezk, R Li, A Evans, F Luessi, F Zipp, PS Giacomini, J Antel, ... Neurology-Neuroimmunology Neuroinflammation 4 (3), 2017 | 85 | 2017 |
| Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis I Mexhitaj, MH Nyirenda, R Li, J O’Mahony, A Rezk, A Rozenberg, ... Brain 142 (3), 617-632, 2019 | 80 | 2019 |
| Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS V Fleischer, M Friedrich, A Rezk, U Bühler, E Witsch, T Uphaus, S Bittner, ... Multiple Sclerosis Journal 24 (5), 632-641, 2018 | 63 | 2018 |
| Antibody-independent function of human B cells contributes to antifungal T cell responses R Li, A Rezk, H Li, JL Gommerman, A Prat, A Bar-Or The Journal of Immunology 198 (8), 3245-3254, 2017 | 49 | 2017 |
| Canadian B cells in MS Team. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy R Li, A Rezk, Y Miyazaki, E Hilgenberg, H Touil, P Shen, CS Moore, ... Sci. Transl. Med 7 (310), 310ra166, 2015 | 49 | 2015 |
| Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod M Ghadiri, L Fitz-Gerald, A Rezk, R Li, M Nyirenda, D Haegert, ... Multiple Sclerosis Journal 23 (9), 1225-1232, 2017 | 36 | 2017 |
| Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease: A Cross-sectional Study R Li, TF Tropea, LR Baratta, L Zuroff, ME Diaz-Ortiz, B Zhang, K Shinoda, ... Neurology-Neuroimmunology Neuroinflammation 9 (2), 2022 | 35 | 2022 |
| Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis M Ghadiri, A Rezk, R Li, A Evans, PS Giacomini, MH Barnett, J Antel, ... Scientific reports 10 (1), 1-14, 2020 | 32 | 2020 |
| Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age L Zuroff, A Rezk, K Shinoda, DA Espinoza, Y Elyahu, B Zhang, AA Chen, ... EBioMedicine 82, 104179, 2022 | 23 | 2022 |
| Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity K Shinoda, R Li, A Rezk, I Mexhitaj, KR Patterson, M Kakara, L Zuroff, ... Proceedings of the National Academy of Sciences 120 (3), e2207291120, 2023 | 22 | 2023 |
| Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1β and IL-18 JE Rood, A Rezk, J Pogoriler, LS Finn, JM Burnham, MB Josephson, ... Journal of Clinical Immunology 43 (1), 101-108, 2023 | 22 | 2023 |
| Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment U Bühler, V Fleischer, F Luessi, A Rezk, P Belikan, C Graetz, R Gollan, ... Multiple Sclerosis Journal 23 (4), 567-576, 2017 | 21 | 2017 |
